11/14/2011 8:08:03 AM
Pfizer Inc. and Bristol-Myers Squibb Co.’s experimental drug apixaban wasn’t safer or more effective than a standard treatment in stopping blood clots in the legs and lungs of patients after hospitalization, a study found. The trial, reported today at the American Heart Association meeting in Orlando, Florida, is the second to show new anticoagulants don’t provide a benefit in severely ill patients more than Sanofi’s injected drug Lovenox, the current standard. Johnson & Johnson and Bayer AG’s Xarelto failed to beat the standard therapy in a trial reported last April.
comments powered by